Bleeding rates linked to new use of Pradaxa (Dabigatran) are no higher than they are with new users of warfarin, says a new FDA Drug Safety communication report update (November 2, 2012). The FDA (Food and Drug Administration) carried out an evaluation on Pradaxa after receiving several post-marketing reports of bleeding among new users...
More...
More...